Photo: Fred Hutch
Education, Training, Board Certifications
- M.D., University of Manitoba, Canada
- Residency in Internal Medicine, University of Manitoba
- Fellowship in Hematology, University of Manitoba
- Medical Oncology, American Board of Internal Medicine
Clinical Expertise
- Hematopoietic stem cell transplantation
- Immunotherapy
Affiliations
Research and/or clinical interests
Dr. Stan Riddell is a world leader in developing immunotherapies, which harness the power of the immune system to fight cancers and dangerous infections. His research focuses on detailing the complex biology of immune cells called T cells and pioneering therapies that use genetically reprogrammed T cells to specifically recognize and destroy diseased cells. These therapeutic T cells zero in on specific protein targets known as antigens, using either natural molecules called T cell receptors or synthetic molecules called chimeric antigen receptors. Chimeric antigen receptors, also known as CARs, combine elements from T cell receptors and from other immune cell-produced antibody molecules. His team’s breakthroughs are helping researchers make progress for patients who need better therapies.
